2020 ASCO Virtual Direct™ Highlights

 

GI
11:26

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced HCC: Is Novel Tremelimumab/Durvalumab Regimen Active? What Is the ORR With 1L Lenvatinib and Pembro?

FEATURING Kit Wong
  • 30 views
  • December 4, 2020
06:33

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Resectable Pancreatic Ductal Adenocarcinoma: Is There a Difference Between Perioperative FOLFIRINOX vs. Gem / nab-P in Efficacy?

FEATURING Kit Wong
  • 21 views
  • December 4, 2020
07:07

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Resectable GE Adenocarcinoma: Does Perioperative FLOT/Ramucirumab Improve pCR Compared to FLOT?

FEATURING Kit Wong
  • 32 views
  • December 4, 2020
06:33

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ Esophageal Adenocarcinoma: Does the Addition of Trastuzumab to Trimodality Treatment Improve DFS?

FEATURING Kit Wong
  • 143 views
  • December 4, 2020
07:24

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Stage III CRC: Are Patients with Stage III Colon Cancer Well-Served With 3 Months of Chemotherapy?

FEATURING Chloe Atreya
  • 1,586 views
  • August 13, 2020
  • 11
06:09

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on BRAFV600E mCRC: How Effective Is FDA Approved 2L Encorafenib + Cetuximab?

FEATURING Chloe Atreya
  • 89 views
  • August 20, 2020
10:08

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ mCRC: Did Trastuzumab Deruxtecan Demonstrate Activity in Patients With HER2-Expressing Disease Who Are Refractory to Standard Therapies?

FEATURING Chloe Atreya
  • 140 views
  • August 20, 2020
  • 1
07:34

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Data on Pembro vs. Chemo in MSI-H mCRC: Is There a Clinically Meaningful and Statistically Significant Difference in PFS?

FEATURING Chloe Atreya
  • 101 views
  • August 20, 2020